A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemiaSrđan Verstovšek, Josef T. Prchal, Celine Pitou et al.|Leukemia Research|2017Cited by 41
Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)Srđan Verstovšek, Josef T. Prchal, Ruben A. Mesa et al.|Blood|2013Cited by 24